Related Experiment Videos

Biologic therapies in juvenile idiopathic arthritis: why and for whom?

L J McCann1, P Woo

  • 1Royal Liverpool NHS Trust,Alder Hey, Liverpool. liza.mccann@rlc.nhs.uk

Acta Reumatologica Portuguesa
|April 25, 2007
PubMed

Insights

Understanding juvenile arthritis (JA) influences offers new therapeutic targets. Early, aggressive treatment is key to prevent disability, with biologic therapies showing promise for resistant cases.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Genetics

Background:

  • Juvenile arthritis (JA) pathogenesis involves complex pathophysiological, genetic, and environmental factors.
  • Early intervention is crucial to prevent long-term disability in children with arthritis.
  • Standard therapies are insufficient for some children, necessitating alternative treatment strategies.

Purpose of the Study:

  • To review current biologic treatment options for pediatric arthritis.
  • To examine the evidence supporting the use of these biologic therapies.
  • To highlight the need for further research into JA's immunological and genetic profiles.

Main Methods:

  • Literature review of current biologic treatments for juvenile arthritis.
  • Analysis of evidence supporting the efficacy and safety of these therapies.
  • Discussion of ongoing research needs and pharmacovigilance.

Main Results:

  • Biologic therapies represent emerging and exciting alternative medications for children with refractory JA.
  • Continued research is essential to elucidate the immunological and genetic underpinnings of JA.
  • Pharmacovigilance is critical for assessing the efficacy and side effect profiles of new treatments.

Conclusions:

  • Biologic treatments offer new hope for managing juvenile arthritis, particularly in treatment-resistant cases.
  • A comprehensive, multidisciplinary approach including physiotherapy, occupational therapy, and specialist liaison is vital.
  • Further research into genetic and immunological factors is required for improved disease control and targeted therapies.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...